GFG Capital’s Takeda Pharmaceutical TAK Stock Holding History

GFG Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-213	Closed	-$3.29K	–	311
2025 Q2	$3.29K	Buy	+213	New	+$3.15K	﹤0.01%	296

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

GFG Capital's TAK Position: Q3 2025 in Review

GFG Capital sold out of Takeda Pharmaceutical (TAK) in Q3 2025, closing a stake of 213 shares — an estimated $3.29K sold.

GFG Capital first reported a position in TAK in Q2 2025 and held it in 1 quarter. The position peaked at $3.29K in Q2 2025. 329 funds tracked by Wall St. Rank hold TAK as of Q3 2025.

GFG Capital reported no remaining Takeda Pharmaceutical position as of Q3 2025 after selling out during the quarter.
GFG Capital sold 213 Takeda Pharmaceutical shares in Q3 2025, an estimated $3.29K.
GFG Capital first reported a position in Takeda Pharmaceutical in Q2 2025 and held it in 1 quarter.
GFG Capital's Takeda Pharmaceutical position peaked at $3.29K in Q2 2025.
329 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.